EUVIMEDΑνακαλύψτε το EUVIMED
KohortenstudieOpen access · CC BY-NC 4.0

Real-World Outcomes of Treprostinil Treatment in Very-Low-Birth-Weight Infants with Pulmonary Hypertension: A Nationwide Cohort Study

Jieun Jeong, Haemin Kang, Ho Jung Choi, Sohee Oh, Jin A Lee

Neonatal Medicine · 2026-05-31 · 33 (1) · 56-65

DOI: 10.5385/nm.26005 ↗

At a glance

Kohortenstudie in Neonatal Medicine, published on 2026-05-31. Written by Jieun Jeong and 4 co-authors. 26 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Korea National Institute of Health.

ΠερίληψηΒιβλιογραφικά στοιχείαCiteRelated studies

Abstract (original language)

Purpose

Treprostinil is used off-label for refractory pulmonary hypertension (PH) in very-low-birth-weight infants (VLBWI); however, real-world outcome data remain scarce. This study aimed to describe the clinical and long-term neurodevelopmental outcomes of treprostinil-treated VLBWI with PH.

Methods

Data from 21,645 VLBWI in a nationwide, multicenter registry (Korean National Network) admitted between 2013 and 2023 were retrospectively analyzed to identify those receiving treprostinil for PH. Baseline characteristics and in-hospital morbidities were compared between survivors and non-survivors. Long-term neurodevelopmental outcomes at 18–24 months and 3 years of corrected age were evaluated in survivors.

Results

Treprostinil was administered to 2.0% (39/1,962) of VLBWI with PH, typically as combination therapy. Among the 32 infants (14 survivors, 18 non-survivors), in-hospital mortality was 56.3%, predominantly due to cardiopulmonary causes (83.3%). Lower cord blood pH was a potential predictor of mortality (odds ratio, 0.924 per 0.01 increase in pH; 95% confidence interval, 0.812 to 0.989; P=0.016). Survivors had higher rates of moderate-to-severe bronchopulmonary dysplasia, treated patent ductus arteriosus, and retinopathy of prematurity requiring intervention. This likely reflects a time-at-risk bias, as non-survivors died early (median, 9.5 days). By 3 years corrected age, all survivors were weaned off oxygen and PH medications. However, growth failure (87.5%) and developmental delay (50.0%) persisted despite continuous rehabilitation (85.7%) and speech therapy (50.0%).

Conclusion

Treprostinil is reserved for refractory PH, which involves high mortality. Despite discontinuation of cardiopulmonary support, survivors experienced substantial long-term growth failure and neurodevelopmental impairment up to 3 years of age, highlighting the critical need for multidisciplinary follow-up.

Funding

  • Korea National Institute of Health

Cite

APA

Jeong, J., Kang, H., Choi, H. J., Oh, S., & Lee, J. A. (2026). Real-World Outcomes of Treprostinil Treatment in Very-Low-Birth-Weight Infants with Pulmonary Hypertension: A Nationwide Cohort Study. Neonatal Medicine, 33(1), 56-65. https://doi.org/10.5385/nm.26005

Vancouver

Jeong J, Kang H, Choi HJ, Oh S, Lee JA. Real-World Outcomes of Treprostinil Treatment in Very-Low-Birth-Weight Infants with Pulmonary Hypertension: A Nationwide Cohort Study. Neonatal Medicine. 2026;33(1):56-65. doi:10.5385/nm.26005

BibTeX
@article{Jeong2026,
  author = {Jeong, Jieun and Kang, Haemin and Choi, Ho Jung and Oh, Sohee and Lee, Jin A},
  title = {Real-World Outcomes of Treprostinil Treatment in Very-Low-Birth-Weight Infants with Pulmonary Hypertension: A Nationwide Cohort Study},
  journal = {Neonatal Medicine},
  year = {2026},
  volume = {33},
  number = {1},
  pages = {56--65},
  doi = {10.5385/nm.26005}
}
Start for free →